Alcon

From Wikipedia, the free encyclopedia

Template:Short description Script error: No such module "about".

Page Module:Infobox/styles.css has no content.Page Template:Infobox company/styles.css has no content.

Alcon Inc.
Native name
Script error: No such module "Lang".
Company type
Public
Page Template:Plainlist/styles.css has no content.
ISINScript error: No such module "WikidataIB".
IndustryScript error: No such module "WikidataIB".
PredecessorScript error: No such module "WikidataIB".
IncorporatedScript error: No such module "WikidataIB".
FoundedScript error: No such module "WikidataIB".
FounderScript error: No such module "WikidataIB".
DefunctScript error: No such module "WikidataIB".
SuccessorScript error: No such module "WikidataIB".
Headquarters
Geneva
,
Switzerland
Key people
David Endicott (CEO)
ProductsPage Template:Plainlist/styles.css has no content.
RevenueScript error: No such module "WikidataIB".
Script error: No such module "WikidataIB".
Script error: No such module "WikidataIB".
Total assetsScript error: No such module "WikidataIB".
Total equityIncrease Template:US$ (2024)
Number of employees
Script error: No such module "WikidataIB".
ParentScript error: No such module "WikidataIB".
Websitealcon.com
Footnotes / references
[1]

Script error: No such module "Check for conflicting parameters".Script error: No such module "Check for deprecated parameters".

Alcon offices in Johns Creek, Georgia

Alcon Inc. (Template:Langx) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon is incorporated in the Canton of Fribourg, Switzerland, and its global headquarters are located in Geneva,[2][3] but its main operational base is in Fort Worth, Texas, United States, where it employs about 4,500 people.[4]

Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company.[5][6] Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals, focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies.[7]

History

Alcon was founded in 1945 as a small pharmacy in Fort Worth, Texas, United States. It was named for its founders, pharmacists Robert Alexander and William Conner[8] who focused on sterile ophthalmic products.

Nestlé of Switzerland purchased Alcon in 1977.[9] Alcon expanded its manufacturing capability with new plants in South America and Europe and drastically increased its investment in research.[10][11]

In 1979, Alcon acquired Texas Pharmacal Company which became Dermatological Products of Texas (and is now DPT Laboratories).[12]

In 1984, Alcon founded the Technical Excellence Award to promote achievements in R&D excellence and has awarded it to more than 100 recipients. The Alcon product line has expanded from pharmaceuticals to the surgical arena. Today, Alcon has operations in 75 countries and its products are sold in over 180 countries.

Nestlé conducted an initial public offering of 25% of its stake in Alcon in 2002. The stock is traded under the ticker symbol ALC. In July 2008, Novartis purchased approximately 25% of Nestlé's stake in Alcon, with an option to buy Nestlé's remaining shares beginning in 2010.[13] Novartis bought 52% stake from Nestlé for $28.1 Billion. This deal brought the total ownership of Alcon by Novartis to 77%. Beginning January 2010 Novartis formally announced it will be completing the exercise options for finishing purchasing the rest of Alcon and then promptly continue to exercise merger and takeover of Alcon.[14][15]

On March 29, 2010, Alcon acquired Durezol and Zyclorin from Sirion Therapeutics. Alcon received regulatory approval to acquire the rights of Durezol emulsion in the US and the global rights, excluding Latin America, for Zyclorin from Sirion Therapeutics.[16]

On April 9, 2019, Alcon completed a 100% spin-off from Novartis.[6][17][18] The new standalone company is worth up to 28 billion Swiss francs.[19]

In November 2021, Alcon announced it would acquire Ivantis and their glaucoma surgery stent technology for at least $475 million.[20] In August 2022, Alcon agreed to buy Aerie Pharmaceuticals for US$770 million to enhance its ophthalmic pharmaceutical portfolio.[21][22][23]

In March 2025, Alcon announced its acquisition of LENSAR, maker of the ALLY Robotic Cataract Laser Treatment System, for $356 million, with the transaction expected to close in the second half of 2025.[24]

In September 2025, Alcon announced the acquisition of LumiThera, Inc., a leader in light-based innovations for ophthalmology.[25]

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content."Alcon Inc. 2024 Annual Report (Form 20-F)". SEC.gov. U.S. Securities and Exchange Commission. 2025-02-25.
  2. ^ Page Module:Citation/CS1/styles.css has no content."Alcon Investor FAQs".
  3. ^ Page Module:Citation/CS1/styles.css has no content."Moneyhouse - Alcon AG".
  4. ^ Page Module:Citation/CS1/styles.css has no content.Bounds, Jeff (2020-01-22). "The (Alcon) Family Tree: How One Company Seeded a DFW Life Science Legacy". Dallas Innovates. Retrieved 2023-02-28.
  5. ^ Page Module:Citation/CS1/styles.css has no content."Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business". Alcon. Archived from the original on 2023-02-16. Retrieved 2018-08-03.
  6. ^ a b Page Module:Citation/CS1/styles.css has no content.Smith, Anna (2019-04-10). "Novartis continues to 'reimagine' itself, as Alcon spin-off completed". PharmaTimes. Retrieved 2019-04-10.
  7. ^ Page Module:Citation/CS1/styles.css has no content."Oberpfälzer Adresse für Augen-Korrektur". www.onetz.de (in Deutsch). Retrieved 2020-10-20.
  8. ^ Page Module:Citation/CS1/styles.css has no content."Improving Vision through Innovation Since 1945".
  9. ^ Page Module:Citation/CS1/styles.css has no content.Nicholson, Chris (4 January 2010). "Novartis to Buy Majority of Alcon From Nestlé". The New York Times. Archived from the original on 6 January 2014.
  10. ^ Page Module:Citation/CS1/styles.css has no content."Alcon considering $100 million manufacturing expansion in south Fort Worth". KERA News. 2023-10-24. Retrieved 2024-03-10.
  11. ^ Page Module:Citation/CS1/styles.css has no content."Alcon eyes new $100 million manufacturing plant in Fort Worth". Dallas News. 2023-10-23. Retrieved 2024-03-10.
  12. ^ Page Module:Citation/CS1/styles.css has no content.Taylor, Lisa (28 July 2002). "Permeating a market". San Antonio Business Journal.
  13. ^ Page Module:Citation/CS1/styles.css has no content."Reuters - Novartis announces offer to buy Nestlé's shares in Alcon". [dead link]
  14. ^ Page Module:Citation/CS1/styles.css has no content."Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business". Scribd. Archived from the original on 2023-02-16. Retrieved 2018-08-03.
  15. ^ Page Module:Citation/CS1/styles.css has no content.News Media, A. B. C. "Boston Beer, Urban Outfitters fall, Alcon, Axon Enterprise rise, Wednesday, 2/28/2024". ABC News. Retrieved 2024-03-10.
  16. ^ Page Module:Citation/CS1/styles.css has no content."Alcon Completes Acquisition of Durezol™ and Zyclorin™ from Sirion". Business Wire. March 29, 2010. Retrieved March 16, 2016.
  17. ^ Page Module:Citation/CS1/styles.css has no content."Alcon tops $28 billion market cap in decade's biggest Swiss stock deal". Reuters. 2019-04-09. Archived from the original on April 10, 2019. Retrieved 2019-04-10.
  18. ^ Page Module:Citation/CS1/styles.css has no content."Novartis completes Alcon spin-off". healio.com. April 9, 2019. Retrieved 2020-02-25.
  19. ^ Page Module:Citation/CS1/styles.css has no content.Smith, Anna (2019-04-10). "Novartis continues to 'reimagine' itself, as Alcon spin-off completed". PharmaTimes. Retrieved 2020-01-30.
  20. ^ Page Module:Citation/CS1/styles.css has no content."Alcon agrees $475 million deal to buy U.S. eye surgery company Ivantis". Reuters. 8 November 2021.
  21. ^ Page Module:Citation/CS1/styles.css has no content."Alcon buys the American Aerie Pharmaceuticals for 770 million". Swissinfo (in français). 23 August 2022.
  22. ^ Page Module:Citation/CS1/styles.css has no content.News Media, ABC. "Boston Beer, Urban Outfitters fall, Alcon, Axon Enterprise rise, Wednesday, 2/28/2024". ABC News. Retrieved 2024-03-10.
  23. ^ Page Module:Citation/CS1/styles.css has no content."Alcon posts 2024 outlook, quarterly numbers in line with market view". Reuters.
  24. ^ Page Module:Citation/CS1/styles.css has no content.Harp, Martin David (2025-03-25). "Alcon agrees to purchase LENSAR". Ophthalmology Times. Archived from the original on 2025-04-19. Retrieved 2025-06-07.
  25. ^ Page Module:Citation/CS1/styles.css has no content."Alcon Completes Acquisition of LumiThera". investor.alcon.com. Retrieved 2025-09-25.

Page Module:Side box/styles.css has no content.Page Template:Sister project/styles.css has no content.

Page Template:Plainlist/styles.css has no content.
Script error: No such module "Sister project logo".
Wikimedia Commons has media related to [[commons:Template:If then show|Template:If then show]].

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:Swiss Leader Index companies Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:Pharmaceutical companies of Switzerland Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.

Lua error in package.lua at line 80: module 'Module:Authority control/config' not found.

Retrieved from "http://cosmopedia.co/index.php?title=Alcon&oldid=1224579"